Literature DB >> 16425412

Hepatitis C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappaB activation.

Qing-Jiao Liao1, Lin-Bai Ye, Khalid Amine Timani, Ying-Long She, Xiao-Jun Yang, Li Ye, Zheng-Hui Wu.   

Abstract

AIM: To study the effects of hepatitis C virus (HCV) core and non-structural 5A (NS5A) proteins on nuclear factor-kappaB (NF-kappaB) activity for understanding their biological function on chronic hepatitis caused by HCV infection.
METHODS: Luciferase assay was used to measure the activity of NF-kappaB in three different cell lines cotransfected with a series of deletion mutants of core protein alone or together with NS5A protein using pNF-kappaB-Luc as a reporter plasmid. Western blot and indirect immunofluorescence assays were used to confirm the expression of proteins and to detect their subcellular localization, respectively. Furthermore, Western blot was also used to detect the expression levels of NF-kappaB/p65, NF-kappaB/p50, and inhibitor kappaB-a (IkappaB-a).
RESULTS: The wild-type core protein (C191) and its mutant segments (C173 and C158) could activate NF-kappaB in Huh7 cells only and activation caused by (C191) could be enhanced by NS5A protein. Moreover, the full-length core protein and its different deletion mutants alone or together with NS5A protein did not enhance the expression level of NF-kappaB. The NF-kappaB activity was augmented due to the dissociation of NF-kappaB-IkappaB complex and the degradation of IkappaB-a.
CONCLUSION: NF-kappaB is the key transcription factor that can activate many genes that are involved in the cellular immune response and inflammation. Coexpression of the full-length core protein along with NS5A can enhance the NF-kappaB activation, and this activation may play a significant role in chronic liver diseases including hepatocellular carcinoma associated with HCV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425412      PMCID: PMC4355782          DOI: 10.3748/wjg.v11.i41.6433

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis.

Authors:  D I Tai; S L Tsai; Y M Chen; Y L Chuang; C Y Peng; I S Sheen; C T Yeh; K S Chang; S N Huang; G C Kuo; Y F Liaw
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  The repressive activity of hepatitis C virus core protein on the transcription of p21(waf1) is regulated by protein kinase A-mediated phosphorylation.

Authors:  E Y Jung; M N Lee; H Y Yang; D Yu; K L Jang
Journal:  Virus Res       Date:  2001-11-05       Impact factor: 3.303

4.  Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation.

Authors:  D Y Jin; H L Wang; Y Zhou; A C Chun; K V Kibler; Y D Hou; H Kung; K T Jeang
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

5.  Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65.

Authors:  Alison M O'Mahony; Mauricio Montano; Katrien Van Beneden; Lin-Feng Chen; Warner C Greene
Journal:  J Biol Chem       Date:  2004-02-12       Impact factor: 5.157

6.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation.

Authors:  Micah Luftig; Teruhito Yasui; Vishal Soni; Myung-Soo Kang; Nils Jacobson; Ellen Cahir-McFarland; Brian Seed; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

8.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.

Authors:  S J Polyak; D M Paschal; S McArdle; M J Gale; D Moradpour; D R Gretch
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

9.  The hepatitis C virus core protein interacts with NS5A and activates its caspase-mediated proteolytic cleavage.

Authors:  P Y Goh; Y J Tan; S P Lim; S G Lim; Y H Tan; W J Hong
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

10.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.

Authors:  M J Gale; M J Korth; N M Tang; S L Tan; D A Hopkins; T E Dever; S J Polyak; D R Gretch; M G Katze
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

View more
  4 in total

1.  Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality.

Authors:  Bhupesh K Prusty; Suresh Hedau; Ajay Singh; Premasis Kar; Bhudev C Das
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

2.  Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress.

Authors:  Howard E Boudreau; Suzanne U Emerson; Agnieszka Korzeniowska; Meghan A Jendrysik; Thomas L Leto
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

3.  Oncogenic potential of hepatitis C virus proteins.

Authors:  Arup Banerjee; Ratna B Ray; Ranjit Ray
Journal:  Viruses       Date:  2010-09-27       Impact factor: 5.818

4.  HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice.

Authors:  Michael A Joyce; Kathie-Anne Walters; Sue-Ellen Lamb; Mathew M Yeh; Lin-Fu Zhu; Norman Kneteman; Jason S Doyle; Michael G Katze; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.